AbbVie stock rose after the pharmaceutical company reported quarterly earnings that beat analysts' expectations and raised guidance early Friday.

First-quarter adjusted earnings per share (EPS) were $2.46 on sales of $13.3 billion, comfortably above analysts' call of $2.38 on sales of $12.9 billion, according to FactSet.

Shares rose 3.3% in premarket trading immediately after the results.

The company raised its full-year profit guidance and now sees adjusted EPS for 2025 of between $12.09 and $12.29, up from between $11.99 and $12.19 previously.

The guidance doesn't reflect shifts in U.S. trade policy -- including pharmaceutical sector tariffs -- that could affect its business going forward, the drugmaker said.

AbbVie stock is up 1.5% so far this year -- outperforming the benchmark S&P 500 index, which is down 6.8% over the same period.